Kornimate/medical-research-clean huggingface dataset:
dealcoholized muscadine wine and skin health in women

Conditions: Skin Health

Summary: the objective of this clinical trial is to determine the activity of dealcoholized muscadine wine to alleviate oxidative stress, inflammation, skin photoaging, and alter gut microbiome in women 40-67 years of age. the investigators hypothesize that dealcoholized muscadine wine daily for 42 days will significantly alleviate oxidative stress, inflammation, skin photoaging, and alter the gut microbiome in women compared to drinking sugar water.

aging of the skin is characterized by wrinkling, sagging, and laxity. about 80% of facial skin aging is classified as extrinsic, or photoaging because it results from exposure to uv light of the sun that causes oxidative stress the remaining 20% of facial aging is the intrinsic type which is partially caused by the accumulation of proteins that are modified by reactive carbonyls in a reaction known as protein glycation. aging also shifts the composition of the gut microbiome in at least 35 genera towards an unhealthy state of dysbiosis. previous studies showed that muscadine polyphenols inhibited protein glycation under a simulated physiological condition. additional experiments using cell culture and mice showed that dealcoholized muscadine wine alleviated inflammation and protected against dysbiosis in the gut. the objective of this research is to confirm the health benefits of muscadine wine polyphenols in a clinical trial. the investigators hypothesize that dealcoholized muscadine wine consumption in women 40-65 years old will alleviate skin photoaging and skin conditions by decreasing oxidative stress and inflammation. it is also expected to improve the composition of the gut microbiome.

Eligibility criteria:
inclusion criteria: * healthy, * bmi 20.0-29.9 * fitzpatrick skin type 2 and 3. exclusion criteria: * pregnancy * breast-feeding * smoking * alcohol use * history of skin cancer * intake of medication that might influence the outcome of the study * sunbathing or the use of tanning bed * intake of vitamin/mineral supplements
detection of melanoma markers in lymph nodes or peripheral blood of patients with melanoma

Conditions: Melanoma (Skin)

Summary: rationale: diagnostic procedures may improve the ability to detect the presence or recurrence of disease. purpose: diagnostic trial to detect melanoma markers in the lymph nodes or peripheral blood of patients who have melanoma.

objectives: * determine the feasibility of performing reverse transcriptase-polymerase chain reaction (rt-pcr) for five different tumor antigen genes using lymph node samples or peripheral blood from patients with melanoma. * determine the ability of pcr-positive lymph nodes or peripheral blood to predict relapse of disease in these patients. * determine the correlation of positive pcr results from peripheral blood with disease stage. outline: lymph node biopsies or peripheral blood are obtained from patients. these specimens are examined by nested reverse transcriptase-polymerase chain reaction (rt-pcr) and analyzed for various tumor antigens. patients may choose to be told the results of this testing, but the results do not influence or change the planned therapy. brief counseling is required to discuss the results and their potential implications. patients are followed for at least 2 years. projected accrual: a total of 30 patients for the lymph node portion and 80 patients (20 per stage of disease) for the peripheral blood portion will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * clinically proven melanoma with indication to perform sentinel lymph node biopsy or elective lymph node dissection or * histologically proven or diagnosis highly suspicious for melanoma patient characteristics: age: * any age performance status: * not specified life expectancy: * not specified hematopoietic: * platelet count greater than 50,000/mm\^3 * hemoglobin greater than 7 g/dl hepatic: * pt less than 15 sec * ptt less than 30 sec renal: * not specified other: * no psychiatric illness that precludes compliance * no other concurrent malignancy prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage i melanoma stage ii melanoma stage iii melanoma stage iv melanoma
severe acute respiratory infections (sari) in belgium (2011-2020)

Conditions: Influenza Viral Infections; Respiratory Viral Infection; Severe Acute Respiratory Infection

Summary: the belgian severe acute respiratory infections network (belsari-net) was implemented during the influenza season 2011-2012 following the recommendations of the world health organization (who) to monitor severity of influenza viruses in hospitals. the network is composed of 6 hospitals throughout the country, two in each administrative region (flanders, wallonia and brussels-capital), and operates during the influenza epidemic period (from the last week of december or first/second week of january to the third/last week of april, depending on when influenza virus circulation is detected by the general population, based on the influenza-like illness (ili) network of general practitioners). enrollment is performed for all cases matching the sari case definition (based on who's case definition) and accepting to take part. a respiratory specimen is sampled systematically from each participant, and detailed clinico-epidemiological data, such as information on age, sex, symptoms and potential risk factors such as pregnancy or comorbidities (chronic respiratory diseases, asthma, chronic cardiovascular diseases, renal insufficiency, obesity, diabetes, hepatic or renal insufficiency, immunodeficiency, neuromuscular disease, pregnancy) is also collected. participants are followed up during hospitalization for the occurrence of complications (detection of pneumonia based on chest radiography, development of acute respiratory distress syndrome (ards), requirement for respiratory assistance and/or for extracorporeal membrane oxygenation (ecmo), admission in intensive care unit (icu)), or death (all-cause death). the current project includes all the samples received by the belgian national influenza centre (nic) during the influenza seasons 2011-2012 till 2019-2020.


Eligibility criteria:
inclusion criteria: * all pediatric and adult patients admitted to one of the 6 sentinel hospitals during the active surveillance and fulfilling the case definition of acute respiratory infection with onset within the last ten days, with history of fever or measured fever of ≥38°c, with cough and/or dyspnea, and overnight hospitalization. exclusion criteria: * nosocomial infection, i.e. symptoms appearing after admission

Keywords: sentinel surveillance
immunologic memory (supp. of atn 024)

Conditions: HIV Infections

Summary: this is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis b surface antigen in hiv-infected and hiv-uninfected adolescents. this is a substudy of atn 024 and atn 025. this substudy will compare cellular immune response in responders and nonresponders to immunization and also evaluate the relationship of these factors to the persistence of known correlates of serologic protection for the hepatitis b virus.

this substudy will enroll volunteers from participants of atn 024 and atn 025. participants in atn 024 are hiv-infected youths aged 12-24 years while participants in atn 025 are hiv-uninfected youths aged 12-17 years. these youths must also be negative for hbv core antibody, hbv surface antigen, and hbv surface antibody to be eligible. blood will be drawn from study participants prior to immunization, 1 month after completion of primary immunization and at study exit (week 72 for atn 024 and week 76 for atn 025) for cytokine assays and enumeration of antibody-secreting cells. in addition, the antibody to hbv surface antigen will be determined 2 and 4 weeks after supplemental immunization in nonresponders to the primary series and at study exit. this laboratory substudy is designed to evaluate some aspects of cellular immune response to hepatitis b vaccination that are directly related to the generation and durability of antibody response to hbv surface antigen in hiv-infected and hiv-uninfected adolescents. cytokine production by peripheral mononuclear cells will be determined following in-vitro stimulation, and antibody-secreting cells will be enumerated.

Eligibility criteria:
inclusion criteria: * subjects that are eligible for participation in atn 024 and atn 025 are eligible for atn 048. subjects consented for atn 024 or atn 025 should be consented for atn 048 at the same time. a written informed assent/consent must be obtained from the subject along with written parental/legal guardian permission as determined by the local irb before any study-related procedures are performed.

Keywords: hepatitis b vaccines hiv-infected adolescents hepatitis b infection
effect of location of tetanic stimuli on photoplethysmogram

Conditions: Stress Reaction

Summary: the effect of the location of tetanic stimulus on photoplethysmography signals will be studies in patients under general anesthesia.

a 5 second 100 hz 70 ma tetanic stimulus will be applied to three different locations in a random order in patients who are under general anesthesia. tetanic stimuli are used routinely during general anesthesia to assess effectiveness of neuromuscular blockade. these tetanic stimuli are noxious stimuli that elicit a stress response which can be quantified using photoplethysmography. this study investigates if the magnitude of the tetanus induced stress response is dependent on the location of the tetanic stimulus as measured by photoplythysmography.

Eligibility criteria:
inclusion criteria: * surgical patients general anesthesia able to consent in english exclusion criteria: * regional anesthesia unable to consent in english under 18 yrs of age

Keywords: photoplethysmography stress response
psychogenic and neurogenic components in patients with psychogenic or neuropathic pruritus

Conditions: Pruritus; Psychogenic Skin Disease; Neuropathic Pain; Itch

Summary: scientific research on pruritus is in intensive development, with significant advances in understanding its pathophysiology. the causes of pruritus are very huge; they can be classified into different categories; we can find dermatological causes, systemic causes, neuropathic or neurological causes, psychogenic or even idiopathic causes. the diagnosis of psychogenic pruritus is often over stated, when no cause is found; therefore, it is important to see what is really relieving from psychic so as not to over-diagnose and adopt a therapy more in line with the real problem of the patient. in daily practice, it seems to have a tendency to separate psychogenic and neurogenic etiologies in the diagnosis of neuropathic or psychogenic pruritus. in the case of patients with psychogenic pruritus and neuropathic pruritus, no study has attempted to study the respective part of psychogenic and neurogenic components. consequently, it would therefore be interesting to assess the areas of superposition and distinction of neuropathic and psychogenic pruritus. the aim of this pilot study is to assess the psychogenic and neurogenic components of psychogenic pruritus and neuropathic pruritus in order to improve understanding of the mechanism and therefore their management. the main objective of this study is to highlight the differences and the potential common characteristics between psychogenic and neuropathic pruritus in order to improve the differential diagnosis between these two pathologies. the secondary objective of this study is to describe the psychogenic and neurogenic characteristics of psychogenic and neuropathic pruritus.

prurineuro : non-interventional single-center prospective study organized and practiced on humans for the development of medical knowledge, in which the data are obtained by validated questionnaires. the duration of participation is estimated at 1 hour. questionnaires used : * critères diagnostiques du prurit psychogène (diagnosis criteria of functional itch disorder or psychogenic pruritus, from the french psychodermatology group) * np5 questionnaire * questionnaire de brest * hads * tas-20 * dn4i

Eligibility criteria:
inclusion criteria: * major (\> 18 years old) * diagnosis of psychogenic pruritus or neuropathic pruritus made in consultation, in day hospital or in hospital, within the dermatology department at the chru de brest * able to understand and agree to sign the information and non-opposition notice * no opposition of the patient exclusion criteria: * patient under legal protection (guardianship, curatorship) * minor (\<18 years old) * acute or chronic condition which could limit the patient's ability to the study's participation * inability to understand and sign the information and non-opposition notice * refusal to give no opposition

Keywords: psychogenic pruritus neuropathic pruritus psychogenic component neurogenic component
exploratory pilot study on the prolonged use of the able exoskeleton in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the goal of this study is to explore the potential clinical benefits of the able exoskeleton as part of a rehabilitation program in people with multiple sclerosis. the main question it aims to answer is: can a rehabiliation program with the able exoskeleton help to mantain the physical and psychosocial health of people with multiple sclerosis? participants will: * have a gait training session of 60 min with the exoskeleton once a week for 12 months at the clinic * have an evaluation (tests and questionnaires) every 3 months at the clinic


Eligibility criteria:
inclusion criteria: * 18 to 70 years old * diagnosed with multiple sclerosis * currently undergoing outpatient physical therapy treatment at the investigation site * ability to give informed consent exclusion criteria: * significant osteoporosis that may increase the risk of fracture * unresolved fractures in the pelvis or extremities, or history of fragility fractures in the lower extremities in the last 2 years * spinal instability (or spinal orthoses, unless authorized by a physician) * severe spasticity: level 4 on the modified ashworth scale * orthostatic hypotension. inability to tolerate a minimum of 30 minutes standing * uncontrolled autonomic dysreflexia * medical instability * unstable cardiovascular system (cvs), hemodynamic instability, untreated hypertension (sbp\>140, dbp\>90 mmhg), unresolved deep venous thrombosis (dvt) * serious comorbidities, including any condition that a physician deems inappropriate for use of the able exoskeleton or to complete participation in the study * skin integrity problems on the contact surfaces of the device or that would prevent sitting * grade i or higher on epuap (european pressure ulcer advisory panel, 2019) on areas that will be in contact with the exoskeleton * colostomy * anthropometric measurements outside the values compatible with able exoskeleton. in particular, height not between 1.5-1.9 m, or weight over 100 kg * anatomical constraints (such as eg length differences, users unable to position themselves inside the device) that are incompatible with the device * restrictions in range of motion that prevent normal gait from being achieved or preventing the completion of a normal transition from sitting to standing or standing to sitting * heterotopic ossification * known pregnancy or breastfeeding * cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures

Keywords: gait training wearable exoskeleton multiple sclerosis
efficacy study of nebulized morphine and intravenous morphine in post traumatic pain

Conditions: Post Traumatic Pain

Summary: in the emergency department, 60% of patients have an acute pain. appropriate management of acute pain is a public health priority according to who recommendations. nebulized morphine has been extensively studied in children but less well in adults. it offers a non-invasive route for systemic drug delivery, more rapid and less invasive than intravenous (iv) method.


Eligibility criteria:
inclusion criteria: * post-traumatic pain with visual analog pain scale( vaps) ≥ 50% * age between 8 and 50 years. exclusion criteria: * glasgow coma scale (gcs)\< 14, * severe injury , * hypotension : blood systolic pressure \< 90 mmhg, * bradypnea \< 12 cpm or sao2\< 90%, * chronic pain treatment, * aspirin or paracetamol treatment within 6 hours of emergency presentation, * nasal trauma, rhinitis, nasal obstruction, * incapacity to cooperate, * opiate allergy, * drug addiction, * pregnancy, breast feeding, * severe renal and liver failure and chronic obstructive pulmonary disease(copd)

Keywords: nebulized morphine intravenous morphine post traumatic pain emergency department
contrast enhanced ultrasound, endoleak detection following evar v1.3

Conditions: Endoleak; Abdominal Aortic Aneurysm

Summary: a single site cross-sectional comparison of paired diagnostic imaging modalities. this study will show the sensitivity and specificity of ceus in detecting the various types of endoleaks, in comparison to tcta, following evar. it will collect data to allow comparison of diagnostic accuracy across modalities including cdu, ceus and tcta. it will collect time taken to perform the various types of scan, to allow healthcare costs to be calculated for each imaging modality.

this study will show the sensitivity and specificity of ceus in detecting the various types of endoleaks, in comparison to tcta, following evar. it will collect data to allow comparison of diagnostic accuracy across modalities including cdu, ceus and tcta. it will collect time taken to perform the various types of scan, to allow healthcare costs to be calculated for each imaging modality. collected data will be analysed regarding two novel hypothesised methods of using ceus information: the first is recording temporal delay between contrast in graft and contrast in endoleak to define endoleak type. potentially this could be used as a faster method of defining endoleak type in a surveillance programme. the second is to identify/refute correlation between ceus contrast to appear in endoleak vs tcta contrast to appear in endoleak. if an association can be established, ceus timings could potentially then be used to time 'standard' cta phases to improve ctas diagnostic accuracy.

Eligibility criteria:
inclusion criteria: 1. aged 18 or over 2. able to give informed consent 3. undergone an evar of infra-renal abdominal aortic aneurysm 4. planned for cta of evar exclusion criteria: 1. unable to receive cta contrast allergy, insufficient renal function for standard outpatient contrast study (egfr \<45) overactive thyroid gland 2. unable to receive ceus contrast previous reaction to sonovue (ultrasound contrast) allergy to sulphur hexafluoride (used in electrical industry in circuit breakers, switch gears \& electrical equipment) recent acute coronary syndrome or unstable angina, typical angina at rest or frequent or repeated angina/chest pain - all within previous 7 days recent coronary intervention 3. previous embolization of artery in region of evar (affects imaging quality) 4. bmi \>30 (affects imaging quality)
prospective analysis of restorelle in the treatment of uterine prolapse

Conditions: Uterine Prolapse

Summary: the purpose of this study is to determine the long term performance of restorelle system for the treatment of uterine prolapse.

this study is being done to evaluate the performance of the restorelle system, which uses smartmesh - an ultra-lightweight mesh for uterine prolapse management. most patients undergo a hysterectomy i.e. removal of the uterus when they have a prolapse. however, this has often been found to be an unnecessary operation. the investigators are studying the use of the restorelle mesh system to preserve the uterus when there is a uterine prolapse.

Eligibility criteria:
inclusion criteria: 1. subject is female. 2. subject is at least 18 years of age. 3. subjects who have already made the decision to proceed with uterine prolapse surgery using restorelle mesh. 4. subject has uterine prolapse defined by prolapse quantification system assessment (popq) score of c -2 or greater. 5. subject reports a bothersome bulge they can see or feel per pelvic floor distress inventory short form 20 (pfdi-20) question 3, response of 2 or higher (i.e. response of "somewhat", "moderately" or "quite a bit"). 6. subject is willing to provide written informed consent. 7. subject is willing and able to comply with follow-up regimen. exclusion criteria: 1. subject is pregnant or intends to become pregnant in the future. 2. subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder or cervical). 3. subject has undergone any previous repair for pelvic organ prolapse. 4. subject has undergone a hysterectomy. 5. subject lacks competency of the english language.